Wegovy

Do not take it if

From the package leaflet in EMA’s product information, p. 134.

How to take it

These directions are for this exact strength and form. Another one is different.

• Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.
• How much to use Adults Your treatment will start at a low dose which will be gradually increased over 16 weeks of treatment.
• When you first start using Wegovy, the starting dose is 0.25 mg once weekly.
• Your doctor will instruct you to gradually increase your dose every 4 weeks until you reach the recommended dose of 2.4 mg once weekly.
• Your doctor may instruct you to increase your dose to 7.2 mg once weekly after a minimum of 4 weeks on the 2.4 mg.
• The maximum dose is 7.2 mg once weekly.• In case you are feeling very bothered by sickness (nausea) or by being sick (vomiting) talk with your doctor about delaying dose escalation or lowering to the previous dose until symptoms have improved.
• Usually, you will be told to follow the table below.
• Dose escalation Weekly dose Week 1–4 0.25 mg Week 5–8 0.5 mg Week 9–12 1 mg Week 13–16 1.7 mg From week 17 2.4 mg From week 21 2.4 mg or 7.2 mg Your doctor will assess your treatment on a regular basis.
• Adolescents (above 12 years of age)
• For adolescents, the same dose escalation schedule as for adults should be applied (see above). The dose should be increased until 2.4 mg (maintenance dose) or maximum tolerated dose has been reached. Weekly doses higher than 2.4 mg are not recommended.
• How Wegovy is given Wegovy is given as an injection under the skin (subcutaneous injection). Do not inject it into a vein or muscle.
• The best places to give the injection are the front of your upper arm, upper legs or stomach.
• Before you use the pen for the first time, your doctor, pharmacist or nurse will show you how to use it.
• Detailed instructions on how to use the pen are on the other side of this leaflet.
• People with type 2 diabetes Tell your doctor if you have type 2 diabetes. Your doctor may adjust the dose of your diabetes medicines to prevent you from getting low blood sugar.
• When to use Wegovy
• You should use this medicine once a week and if possible, on the same day each week.
• You can give yourself the injection at any time of the day – regardless of meals.
• If necessary, you can change the day of your weekly injection of this medicine as long as it has been at least 3 days since your last injection. After selecting a new dosing day, continue with once a week dosing.
• If you use more Wegovy than you should Talk to your doctor straight away. You may get side effects such as feeling sick (nausea), being sick (vomiting) or have diarrhoea, which may cause dehydration (loss of fluids).
• If you forget to use Wegovy If you forgot to inject a dose and:
• it is 5 days or less since you should have used Wegovy, use it as soon as you remember. Then inject your next dose as usual on your scheduled day.
• it is more than 5 days since you should have used Wegovy, skip the missed dose. Then inject your next dose as usual on your next scheduled day.
• Do not use a double dose to make up for a forgotten dose.
• If you stop using Wegovy Do not stop using this medicine without talking to your doctor.
• If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

From the package leaflet in EMA’s product information, p. 136–137.

Warnings and precautions

From the package leaflet in EMA’s product information, p. 134–135.

Pregnancy and breastfeeding

From the package leaflet in EMA’s product information, p. 135.

Other medicines

From the package leaflet in EMA’s product information, p. 135.

Driving and using machines

• Wegovy is unlikely to affect your ability to drive and use machines. Some patients may feel dizzy when taking Wegovy mainly during the first 4 months of treatment (see section 4). If you feel dizzy be extra careful while driving or using machines. If you need any further information, talk to your doctor, pharmacist or nurse.
• People with type 2 diabetes If you use this medicine in combination with a sulfonylurea or insulin, low blood sugar (hypoglycaemia) may occur which may reduce your ability to concentrate. Avoid driving or using machines if you get any signs of low blood sugar. See section 2, ‘Warnings and precautions’ for information on increased risk of low blood sugar and section 4 for the warning signs of low blood sugar. Talk to your doctor for further information.
• Wegovy contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium- free’.

From the package leaflet in EMA’s product information, p. 135.

Side effects

• Like all medicines, this medicine can cause side effects, although not everybody gets them.
• Serious side effects Common (may affect up to 1 in 10 people)
• Complications of diabetic eye disease (diabetic retinopathy). If you have diabetes you should inform your doctor if you experience eye problems, such as changes in vision, during treatment with this medicine.
• Uncommon (may affect up to 1 in 100 people)
• Inflamed pancreas (acute pancreatitis). Signs of inflamed pancreas may include severe and long- lasting pain in your stomach, the pain may move to your back. You should see your doctor immediately if you experience such symptoms.
• Rare (may affect up to 1 in 1 000 people)
• Severe allergic reactions (anaphylactic reactions, angioedema). You should seek immediate medical help and inform your doctor straight away if you get symptoms such as breathing difficulty, swelling, light-headedness, fast heartbeat, sweating and loss of consciousness or rapid swelling under the skin in areas such as the face, throat, arms and legs, which can be life threatening if throat swelling blocks the airway.
• Very Rare (may affect up to 1 in 10 000 people)
• A medical condition of the eye called non-arteritic anterior ischaemic optic neuropathy (NAION), which may cause loss of vision to one of your eyes without any pain. You should immediately contact your doctor if you notice sudden or gradually worsening eyesight (see section 2: “Sudden changes to your eyesight”).
• Not known (frequency cannot be estimated from the available data)
• Bowel obstruction. A severe form of constipation with additional symptoms such as stomach ache, bloating, vomiting etc.
• Other side effects Very common (may affect more than 1 in 10 people)
• headache
• feeling sick (nausea)
• being sick (vomiting)
• diarrhoea
• constipation
• stomach pain
• feeling weak or tired
• these are mainly seen during dose escalation and usually go away over time.
• Common (may affect up to 1 in 10 people)
• feeling dizzy
• upset stomach or indigestion
• burping
• gas (flatulence)
• bloating of the stomach
• inflamed stomach (‘gastritis’) – the signs include stomach-ache, feeling sick (nausea) or being sick (vomiting)
• reflux or heartburn – also called ‘gastro-oesophageal reflux disease’
• gallstones
• hair loss – may occur more frequently with semaglutide 7.2 mg
• injection site reactions
• change in the way food or drink tastes
• change in skin sensation – this usually goes away over time and may happen more frequently with semaglutide 7.2 mg
• low blood sugar (hypoglycaemia) in patients with type 2 diabetes.
• The warning signs of low blood sugar may come on suddenly. They can include: cold sweat, cool pale skin, headache, fast heartbeat, feeling sick (nausea) or very hungry, changes in vision, feeling sleepy or weak, feeling nervous, anxious or confused, difficulty concentrating or shaking.
• Your doctor will tell you how to treat low blood sugar and what to do if you notice these warning signs.
• Low blood sugar is more likely to happen if you also take a sulfonylurea or insulin. Your doctor may reduce your dose of these medicines before you start using this medicine.
• Uncommon (may affect up to 1 in 100 people)
• low blood pressure
• feeling dizzy or lightheaded on standing or sitting up because of a drop in blood pressure
• fast heartbeat
• increase of pancreatic enzymes (such as lipase and amylase) shown in blood tests
• a delay in the emptying of the stomach.
• Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

From the package leaflet in EMA’s product information, p. 137–138.

How to store it

• Keep this medicine out of the sight and reach of children.
• Do not use this medicine after the expiry date which is stated on the pen label and carton after ‘EXP’.
• The expiry date refers to the last day of that month.
• Store in a refrigerator (2°C – 8°C). Do not freeze. Keep away from the cooling element. Always store the pen in the original carton in order to protect from light.
• Wegovy may be stored unrefrigerated for up to 28 days at a temperature not above 30°C.
• Discard the pen if it has been exposed to light or temperatures above 30°C, has been out of the refrigerator for more than 28 days, or has been frozen.
• Do not use this medicine if you notice that the solution is not clear and colourless.
• After use: The pen is for single use and contains one dose only. Discard pen after use.
• Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

From the package leaflet in EMA’s product information, p. 138–139.

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

Details

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).

Report wrong or outdated information on this page

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

See every product with Semaglutide